SpringWorks Therapeutics

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that identifies and advances promising scientific and pioneering therapeutic approaches for drug development targeting severe rare diseases and cancer. SpringWorks Therapeutics was launched in 2017 with a portfolio of promising clinical-stage therapies, backed by strong financial support from a group of leading life science investors and pharmaceutical industry partners. The company’s lead pipeline program is an oral small molecule drug called Nirogacestat—a gamma-secretase inhibitor—for rare oncology indications, currently in Phase III clinical trials for the treatment of desmoid tumors: In August 2017, Nirogacestat received both Orphan Drug and Fast Track designations, and its Phase III clinical trial commenced in May 2019.